Annual Report

Overview

The report describes IRLAB's 2020 progress in advancing its Parkinson's drug pipeline, including the ongoing Phase IIb/III mesdopetam study in Europe and the US. It highlights the company's move to Nasdaq Stockholm's Main Market and strengthened financial position following capital raising. The report also presents sustainability work organized around employees, responsible dealings, and community involvement.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: 1 January 2020 – 31 December 2020
Publication date: 14 April 2021
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services